Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

A systematic review of clinical outcomes for patients diagnosed with skin cancer spinal metastases
Goodwin, C. Rory , Sankey, Eric W. , Liu, Ann , Elder, Benjamin D. , Kosztowski, Thomas, Lo, Sheng-Fu Larry , Fisher, Charles G. , Gokaslan, Ziya L. , Sciubba, Daniel M. , Clarke, Michelle J. , Goodwin, C Rory

Journal of Neurosurgery: Spine | November 6, 2015 | Volume: 24 | Issue: 5 | Pages: 837-849

10.3171/2015.4.spine15239 | PMID 26544595 Get It

OBJECT Surgical procedures and/or adjuvant therapies are effective modalities for the treatment of symptomatic spinal metastases. However, clinical results specific to the skin cancer spinal metastasis cohort are generally lacking. The purpose of this study was to systematically review the literature for treatments, clinical outcomes, and survival following the diagnosis of a skin cancer spinal metastasis and evaluate prognostic factors in the context of spinal skin cancer metastases stratified by tumor subtype. METHODS The authors performed a literature review using PubMed, Embase, CINAHL, and Web of Science to identify articles since 1950 that reported survival, clinical outcomes, and/or prognostic factors for the skin cancer patient population with spinal metastases. The methodological quality of reviews was assessed using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) tool. RESULTS Sixty-five studies met the preset criteria and were included in the analysis. Of these studies, a total of 25, 40, 25, and 12 studies included patients who underwent some form of surgery, radiotherapy, chemotherapy, or observation alone, respectively. Sixty-three of the 65 included studies were retrospective in nature (Class of Evidence [CoE] IV), and the 2 prospective studies were CoE II. Based on the studies analyzed, the median overall survival for a patient with a spinal metastasis from a primary skin malignancy is 4.0 months; survival by tumor subtype is 12.5 months for patients with basal cell carcinoma (BCC), 4.0 months for those with melanoma, 4.0 months for those with squamous cell carcinoma, 3.0 months for those with pilomatrix carcinoma, and 1.5 months for those with Merkel cell carcinoma (p < 0.0001). The overall percentage of known continued disease progression after spine metastasis diagnosis was 40.1% (n = 244/608, range 25.0%–88.9%), the rate of known recurrence of the primary skin cancer lesion was 3.5% (n = 21/608, range 0.2%–100.0%), and the rate of known spine metastasis recurrence despite treatment for all skin malignancies was 2.8% (n = 17/608, range 0.0%–33.3%). Age greater than 65 years, sacral spinal involvement, presence of a neurological deficit, and nonambulatory status were associated with decreased survival in patients diagnosed with a primary skin cancer spinal metastasis. All other clinical or prognostic parameters were of low or insufficient strength. CONCLUSIONS Patients diagnosed with a primary skin cancer metastasis to the spine have poor overall survival with the exception of those with BCC. The median duration of survival for patients who received surgical intervention alone, medical management (chemotherapy and/or radiation) alone, or the combination of therapies was similar across interventions. Age, spinal region, and neurological status may be associated with poor survival following surgery.
Age-related outcomes following intracranial aneurysm treatment with the Pipeline Embolization Device: a subgroup analysis of the IntrePED registry
Brinjikji, Waleed , Kallmes, David F. , Cloft, Harry J. , Lanzino, Giuseppe

Journal of Neurosurgery | November 6, 2015 | Volume: 124 | Issue: 6 | Pages: 1726-1730

10.3171/2015.5.jns15327 | PMID 26544776 Get It

OBJECT The association between age and outcomes following aneurysm treatment with flow diverters such as the Pipeline Embolization Device (PED) have not been well established. Using the International Retrospective Study of the Pipeline Embolization Device (IntrePED) registry, the authors assessed the age-related clinical outcomes of patients undergoing aneurysm embolization with the PED. METHODS Patients with unruptured aneurysms in the IntrePED registry were divided into 4 age groups: ≤ 50, 51–60, 61–70, and > 70 years old. The rates of the following postoperative complications were compared between age groups using chi-square tests: spontaneous rupture, intracranial hemorrhage (ICH), ischemic stroke, parent artery stenosis, cranial neuropathy, neurological morbidity, neurological mortality, combined neurological morbidity and mortality, and all-cause mortality. The association between age and these complications was tested in a multivariate logistic regression analysis adjusted for sex, number of PEDs, and aneurysm size, location, and type. RESULTS Seven hundred eleven patients with 820 unruptured aneurysms were included in this study. Univariate analysis demonstrated no significant difference in ICH rates across age groups (lowest 1.0% for patients ≤ 50 years old and highest 5.0% for patients > 70 years old, p = 0.097). There was no difference in ischemic stroke rates (lowest 3.6% for patients ≤ 50 years old and highest 6.0% for patients 50–60 years old, p = 0.73). Age > 70 years old was associated with higher rates of neurological mortality; patients > 70 years old had neurological mortality rates of 7.4% compared with 3.3% for patients 61–70 years old, 2.7% for patients 51–60 years old, and 0.5% for patients ≤ 50 years old (p = 0.006). On multivariate logistic regression analysis, increasing age was associated with higher odds of combined neurological morbidity and mortality (odds ratio 1.02, 95% confidence interval 1.00–1.05; p = 0.03). CONCLUSIONS Increasing age is associated with higher neurological morbidity and mortality after Pipeline embolization of intracranial aneurysms. However, the overall complication rates of PED treatment in this group of highly selected elderly patients (> 70 years) were acceptably low, suggesting that age alone should not be considered an exclusion criterion when considering treatment of intracranial aneurysms with the PED.
High-Throughput Long Noncoding RNA Profiling for Diagnostic and Prognostic Markers in Cancer: Opportunities and Challenges
Sun, Zhifu , Sun, Zhifu

Epigenomics | November 6, 2015 | Volume: 7 | Issue: 7 | Pages: 1075-1078

10.2217/epi.15.69 | PMID 26541179 Get It

Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation
Yao, Xiaoxi , Deshmukh, Abhishek , Houten, Holly Van, Sangaralingham, Lindsey R. , Siontis, Konstantinos C. , Piccini, Jonathan P. , Asirvatham, Samuel J. , Friedman, Paul A. , Packer, Douglas L. , Shah, Nilay D. , Van Houten, Holly, Noseworthy, Peter A. , Gersh, Bernard J. , Asirvatham, Samuel J , Yao, Xiaoxi

Journal of the American Heart Association | November 6, 2015 | Volume: 4 | Issue: 11 | Pages: No page available

10.1161/jaha.115.002597 | PMID 26541393 Get It

Background There is significant practice variation in oral anticoagulation ( OAC ) use following catheter ablation for atrial fibrillation. It is not clear whether the risk of cardioembolism increases after discontinuation of OAC following catheter ablation. Methods and Results We identified 6886 patients within a large national administrative claims database who underwent catheter ablation for atrial fibrillation between January 1, 2005, and September 30, 2014. We assessed the effect of time off of OAC by CHA 2 DS 2 ‐ VAS c score (after adjusting for other comorbidities) on risk of cardioembolism, using Cox proportional hazards models. There was an increase in the use of non–vitamin K OAC after ablation from 0% in 2005 to 69.8% in 2014. OAC discontinuation was high, with only 60.5% and 31.3% of patients remaining on OAC at 3 and 12 months, respectively. The rate of discontinuation was higher in low‐risk patients (82% versus 62.5% at 12 months for CHA 2 DS 2 ‐ VAS c 0–1 versus ≥2, respectively; P <0.001). Stroke occurred in 1.4% of patients with CHA 2 DS 2 ‐ VAS c ≥2 and 0.3% of those with CHA 2 DS 2 ‐ VAS c 0 or 1 over the study follow‐up. The risk of cardioembolism in the first 3 months after ablation was increased among those with any time off OAC (hazard ratio 8.06 [95% CI 1.53–42.3], P <0.05). The risk of cardioembolism beyond 3 months was increased with OAC discontinuation among high‐risk patients (hazard ratio 2.48 [95% CI 1.11–5.52], P <0.05) but not low‐risk patients. Conclusion The overall risk of stroke in postablation patients is low; however, OAC discontinuation after ablation is common and is associated with increased risk of cardioembolism for all patients within the first 3 months and for high‐risk patients in the long term. Continuing OAC for at least 3 months in all patients and indefinitely in high‐risk patients appears to be the safest strategy.
Endoscopic ultrasound-guided fine-needle aspiration of a pulmonary artery malignant thrombus
Gincul, Rodica , Gómez, Victoria , Kerr, Sarah E. , Levy, Michael J. , Zhang, Jun , Levy, Michael J.

Endoscopy | November 5, 2015 | Volume: 47 | Issue: S 01 | Pages: E547-E549

10.1055/s-0034-1393319 | PMID 26540306 Get It

Kinematic analysis of wrist motion during simulated colonoscopy in first-year gastroenterology fellows
Ratuapli, Shiva K., Ramirez, Francisco C. , Mohankumar, Deepika, Fleischer, David E., Ruff, Kevin C. , Ruff, Kevin , Wu, Qing Feng , Santello, Marco

Endoscopy International Open | November 5, 2015 | Volume: 03 | Issue: 06 | Pages: E621-E626

10.1055/s-0034-1393061 | PMID 26716123 Get It

Improvement in Quality of Life after Therapy for Mycobacterium abscessus Group Lung Infection. A Prospective Cohort Study
Czaja, Christopher A. , Levin, Adrah, Cox, Christian W. , Daley, Charles L. , Cott, Gary R., Vargas, Daniel

Annals of the American Thoracic Society | November 5, 2015 | Volume: 13 | Issue: 1 | Pages: 40-48

10.1513/annalsats.201508-529oc | PMID 26540302 Get It

Abstract Rationale Mycobacterium abscessus group lung infection is characterized by low cure rates. Improvement in quality of life may be a reasonable treatment goal. Objectives The objective of this study was to evaluate change in quality of life in response to therapy, predictors of improvement in quality of life, and association of quality of life with traditional outcome measures. Methods Forty-seven patients were treated for Mycobacterium abscessus group lung infection (including one with Mycobacterium chelonae) and were followed prospectively for 2 years between December 2009 and May 2012. St. George’s Respiratory Questionnaire (SGRQ) was administered, chest computed tomography (CT) imaging was carried out, and culture data were collected at multiple time points. Predictors of improvement in the SGRQ total score greater than or equal to a minimal clinically important difference (MCID) at 12 months were evaluated. Measurements and Main Results: Patients were 85% female and 94% white, with a mean age of 65 years. Nine (20%) had a genetic diagnosis of cystic fibrosis (none F508del homozygous). Coinfection with Mycobacterium avium complex occurred in 28% and Pseudomonas in 26%. Chest CT imaging universally indicated bronchiectasis and nodules; 51% had lung cavities. Treatment included a mean of 17 months of antibiotics, and lung resection in 34%. Seventeen patients with M. avium complex (36%) and one with Mycobacterium kansasii were treated for coinfection. The mean SGRQ total score (SD) at baseline was 35 (20). At all follow-up time points, the mean SGRQ total score (SD) was significantly lower (better) than at baseline: 27 (17) at 3 months, P &lt; 0.01; 27 (19) at 6 months, P &lt; 0.01; 27 (20) at 12 months, P &lt; 0.01; and 30 (22) at 24 months, P = 0.02. At 12 and 24 months, respectively, 60% and 56% had improvement greater than or equal to the MCID in SGRQ total score. Improvement greater than or equal to the MCID at 12 months was positively associated with a history of respiratory exacerbation, isolate susceptible to imipenem-cilastatin, and lung resection surgery, and negatively associated with nodules &gt;4 mm in diameter on chest CT imaging, but these associations were not statistically significant in multivariable analysis. At 24 months, 16 patients (48%) with complete data were culture negative for 1 year and had discontinued M. abscessus group treatment. Conclusions Quality of life was a sensitive indicator of treatment response and has the potential to be a useful parameter to guide treatment.
Salivary gland FNA: New markers and new opportunities for improved diagnosis
Pusztaszeri, Marc , García, Joaquín J. , Faquin, William C , Pusztaszeri, Marc

Cancer Cytopathology | November 5, 2015 | Volume: 124 | Issue: 5 | Pages: 307-316

10.1002/cncy.21649 | PMID 26539897 Get It

Salivary gland fine‐needle aspiration represents one of the most challenging areas of cytopathology; however, the discovery of several novel and/or next‐generation immunocytochemical and molecular markers for salivary gland tumors has resulted in greater diagnostic accuracy in cytologic diagnosis. In this commentary, recent advances in salivary gland cytopathology are reviewed with a focus on salivary gland tumors associated with gene rearrangements.
The clinical determination of brain death: practice limitations
Rady, Mohamed Y. , Verheijde, Joseph L.

European Journal of Neurology | November 5, 2015 | Volume: 22 | Issue: 12 | Pages: No page available

10.1111/ene.12787 | PMID 26538272 Get It

Assessment of Methods for Rapid Intraoperative Concentration and Selection of Marrow-Derived Connective Tissue Progenitors for Bone Regeneration Using the Canine Femoral Multidefect Model
Luangphakdy, Viviane, Boehm, Cynthia , Hui, Pan , Herrick, James L., Zaveri, Phil, Herrick, James, Muschler, George F.

Tissue Engineering Part A | November 5, 2015 | Volume: 22 | Issue: 1-2 | Pages: 17-30

10.1089/ten.tea.2014.0663 | PMID 26538088 Get It